Status:

COMPLETED

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Lead Sponsor:

Milton S. Hershey Medical Center

Conditions:

Neuroblastoma

Sarcoma

Eligibility:

All Genders

Up to 30 years

Phase:

PHASE1

Brief Summary

RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the t...

Detailed Description

OBJECTIVES: * Determine the toxicity of allogeneic hematopoietic stem cell transplantation, in terms of the incidence of grade 3-4 acute graft-versus-host disease, in young patients with relapsed or ...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of relapsed or refractory solid tumor, including, but not limited to, relapsed neuroblastoma, relapsed Ewing's sarcoma, and relapsed rhabdomyosarcoma
  • No isolated local disease recurrence at the site of the primary tumor \> 1 year after completion of prior therapy
  • No brain tumor or brain metastases
  • Related or unrelated hematopoietic stem cell donor available, meeting 1 of the following criteria:
  • Matched for HLA-A, -B, -C, -DR, and -DQ (9/10 or 10/10 allelles) (marrow or peripheral blood)
  • Matched for HLA-A, -B, and -DR (5/6 or 6/6 allelles) (cord blood)
  • Cord blood specimen must contain ≥ 2 x 10 \^7 nucleated cells/kg body weight
  • PATIENT CHARACTERISTICS:
  • Age
  • 30 and under
  • Performance status
  • ECOG 0-1 OR
  • Lansky 80-100%
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Not specified
  • Hepatic
  • Bilirubin ≤ 3.0 mg/dL
  • Renal
  • Creatinine clearance ≥ 50 mL/min
  • Cardiovascular
  • Ejection fraction ≥ 50%
  • Pulmonary
  • DLCO ≥ 70% OR
  • O\_2 saturation ≥ 95% on room air
  • Other
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Prior autologous stem cell transplantation allowed
  • Chemotherapy
  • Not specified
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • Not specified
  • Surgery
  • Not specified

Exclusion

    Key Trial Info

    Start Date :

    April 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2011

    Estimated Enrollment :

    10 Patients enrolled

    Trial Details

    Trial ID

    NCT00112645

    Start Date

    April 1 2005

    End Date

    February 1 2011

    Last Update

    July 18 2013

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center

    Hershey, Pennsylvania, United States, 17033-0850